Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.

The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers.

Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors.

The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited.

Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.